Mineralys Therapeutics, Inc.
NASDAQMineralys Therapeutics heads into mid-June with a clear tension: short sellers are adding pressure while the stock drifts lower, yet the lending market remains far too loose to suggest a squeeze is imminent. Short interest has climbed meaningfully over the past month — up 12% to 12.4% of the free float, with a further 5.8% week-on-week build adding roughly 540,000 shares to the…
Snapshot as of 22 Jun 2026
Mineralys Therapeutics heads into mid-June with a clear tension: short sellers are adding pressure while the stock drifts lower, yet the lending market remains far too loose to suggest a squeeze is imminent. Short…
Mineralys Therapeutics stumbled into a pivotal week — pricing a dilutive equity offering at a steep discount to buy back royalty obligations on lorundrostat, right as the FDA clock ticks louder. On June 3, the company…
Mineralys Therapeutics heads into its May 21 first-quarter earnings report with one of the more unusual positioning setups in small-cap biotech: short sellers are covering aggressively while options traders have swung…
Mineralys Therapeutics entered its Q1 results week with short sellers quietly adding pressure and options traders having already rotated to a more bullish stance — a setup that frames the next catalyst squarely around…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for MLYS — free to start on ORTEX.
Sign up for free →Open MLYS on ORTEX